irRECIST and iRECIST: the devil is in the details

Ann Oncol. 2017 Jul 1;28(7):1676-1678. doi: 10.1093/annonc/mdx168.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents, Immunological / therapeutic use*
  • CTLA-4 Antigen / antagonists & inhibitors
  • Clinical Trials, Phase II as Topic / methods
  • Clinical Trials, Phase III as Topic / methods
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / pathology*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Response Evaluation Criteria in Solid Tumors*
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Immunological
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor